Rice Hall James & Associates LLC Acquires 765,701 Shares of Revance Therapeutics Inc (NASDAQ:RVNC)

Rice Hall James & Associates LLC boosted its holdings in Revance Therapeutics Inc (NASDAQ:RVNC) by 654.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 882,769 shares of the biopharmaceutical company’s stock after acquiring an additional 765,701 shares during the period. Rice Hall James & Associates LLC’s holdings in Revance Therapeutics were worth $11,450,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of RVNC. Dimensional Fund Advisors LP raised its stake in Revance Therapeutics by 197.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 225,708 shares of the biopharmaceutical company’s stock valued at $4,543,000 after acquiring an additional 149,952 shares during the period. Geode Capital Management LLC raised its stake in Revance Therapeutics by 14.3% in the 4th quarter. Geode Capital Management LLC now owns 385,818 shares of the biopharmaceutical company’s stock valued at $7,766,000 after acquiring an additional 48,325 shares during the period. Jane Street Group LLC bought a new stake in Revance Therapeutics in the 4th quarter valued at $274,000. Legal & General Group Plc raised its stake in Revance Therapeutics by 21.7% in the 4th quarter. Legal & General Group Plc now owns 6,445 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 1,150 shares during the period. Finally, Deutsche Bank AG raised its stake in Revance Therapeutics by 51.1% in the 4th quarter. Deutsche Bank AG now owns 331,820 shares of the biopharmaceutical company’s stock valued at $6,678,000 after acquiring an additional 112,193 shares during the period. Institutional investors and hedge funds own 96.72% of the company’s stock.

NASDAQ RVNC traded down $0.68 on Thursday, reaching $10.63. The stock had a trading volume of 297,024 shares, compared to its average volume of 367,947. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.59 and a current ratio of 5.59. The stock’s fifty day moving average is $12.43. Revance Therapeutics Inc has a 1-year low of $10.37 and a 1-year high of $27.80. The stock has a market capitalization of $494.36 million, a P/E ratio of -2.70 and a beta of 1.00.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.86) EPS for the quarter, meeting analysts’ consensus estimates of ($0.86). Revance Therapeutics had a negative return on equity of 79.28% and a negative net margin of 3,745.97%. Analysts forecast that Revance Therapeutics Inc will post -3.68 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on the company. Mizuho restated a “buy” rating and issued a $37.00 price target on shares of Revance Therapeutics in a research note on Wednesday, April 24th. BidaskClub upgraded Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 31st. ValuEngine upgraded Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 9th. Finally, Barclays started coverage on Revance Therapeutics in a research note on Tuesday, June 11th. They issued an “overweight” rating and a $28.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $33.09.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.

See Also: Why is the price target of stocks important?

Want to see what other hedge funds are holding RVNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revance Therapeutics Inc (NASDAQ:RVNC).

Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.